RMD vs. BSX, MDT, BDX, EW, DXCM, IDXX, STE, HOLX, BAX, and PODD
Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Baxter International (BAX), and Insulet (PODD). These companies are all part of the "health care equipment" industry.
ResMed (NYSE:RMD) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
ResMed currently has a consensus price target of $203.20, indicating a potential upside of 3.13%. Boston Scientific has a consensus price target of $84.76, indicating a potential upside of 13.09%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than ResMed.
ResMed has a net margin of 20.91% compared to Boston Scientific's net margin of 12.00%. ResMed's return on equity of 24.43% beat Boston Scientific's return on equity.
Boston Scientific has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
ResMed has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
In the previous week, Boston Scientific had 42 more articles in the media than ResMed. MarketBeat recorded 56 mentions for Boston Scientific and 14 mentions for ResMed. ResMed's average media sentiment score of 0.60 beat Boston Scientific's score of 0.53 indicating that ResMed is being referred to more favorably in the media.
55.0% of ResMed shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.2% of ResMed shares are owned by insiders. Comparatively, 0.5% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Boston Scientific received 602 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 69.58% of users gave Boston Scientific an outperform vote while only 52.79% of users gave ResMed an outperform vote.
Summary
Boston Scientific beats ResMed on 13 of the 19 factors compared between the two stocks.
Get ResMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
